Patrick Therasse
GlaxoSmithKline (Belgium)(BE)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics
Most-Cited Works
- → New Guidelines to Evaluate the Response to Treatment in Solid Tumors(2000)15,689 cited
- → iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics(2017)2,331 cited
- → RECIST 1.1—Update and clarification: From the RECIST committee(2016)1,838 cited
- → A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer(2003)1,824 cited
- → Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer(2006)1,223 cited
- → Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma(2002)940 cited
- → Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial(2016)493 cited
- → RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group(2016)368 cited
- → Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer(2008)350 cited